GlassScriptPhysician profile
Hidalberto Curnow
NPI 1174681688
$20,888.29
in general payments reported to CMS, 2019-2025
51 companies · $3,861 in 2025
The $3,861 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,273 · 2020: $2,029 · 2021: $2,303 · 2022: $3,328 · 2023: $3,404 · 2024: $3,693 · 2025: $3,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $84.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,872.15 |
| Education | $84.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,838.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,178.93 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Novo Nordisk INC | $2,103.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,527.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,154.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,043.56 | 2019-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $735.64 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $641.47 | 2019-2025 | Jardiance |
| Abbott Laboratories | $628.54 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $610.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $528.81 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $480.50 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $456.21 | 2024-2025 | Zenpep |
| Pfizer INC. | $452.84 | 2019-2025 | |
| Astellas Pharma US INC | $337.65 | 2019-2025 | Veozah |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hidalberto Curnow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.